These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

866 related articles for article (PubMed ID: 18854573)

  • 1. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
    Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
    J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
    Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
    Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
    Chevallier P; Roland V; Mahé B; Juge-Morineau N; Dubruille V; Guillaume T; Vigouroux S; Moreau P; Milpied N; Garand R; Avet-Loiseau H; Harousseau JL
    Leuk Res; 2005 Sep; 29(9):1003-7. PubMed ID: 16038726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CAG-GO therapy for patients with relapsed or primary refractory CD33-positive acute myelogenous leukemia].
    Takahashi W; Nakamura Y; Tadokoro J; Handa T; Arai H; Tokita K; Iso H; Tsurumi S; Sasaki K; Maki K; Mitani K
    Rinsho Ketsueki; 2012 Jan; 53(1):71-7. PubMed ID: 22374527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
    Usui N; Takeshita A; Nakaseko C; Dobashi N; Fujita H; Kiyoi H; Kobayashi Y; Sakura T; Yahagi Y; Shigeno K; Ohwada C; Miyazaki Y; Ohtake S; Miyawaki S; Naoe T; Ohnishi K;
    Cancer Sci; 2011 Jul; 102(7):1358-65. PubMed ID: 21585619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
    Larson RA; Sievers EL; Stadtmauer EA; Löwenberg B; Estey EH; Dombret H; Theobald M; Voliotis D; Bennett JM; Richie M; Leopold LH; Berger MS; Sherman ML; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR
    Cancer; 2005 Oct; 104(7):1442-52. PubMed ID: 16116598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
    Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
    Candoni A; Papayannidis C; Martinelli G; Simeone E; Gottardi M; Iacobucci I; Gherlinzoni F; Visani G; Baccarani M; Fanin R
    Am J Hematol; 2018 May; 93(5):655-663. PubMed ID: 29396857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
    Pilorge S; Rigaudeau S; Rabian F; Sarkozy C; Taksin AL; Farhat H; Merabet F; Ghez S; Raggueneau V; Terré C; Garcia I; Renneville A; Preudhomme C; Castaigne S; Rousselot P
    Am J Hematol; 2014 Apr; 89(4):399-403. PubMed ID: 24375467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
    Tsimberidou A; Cortes J; Thomas D; Garcia-Manero G; Verstovsek S; Faderl S; Albitar M; Kantarjian H; Estey E; Giles FJ
    Leuk Res; 2003 Oct; 27(10):893-7. PubMed ID: 12860008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.
    Feldman EJ; Brandwein J; Stone R; Kalaycio M; Moore J; O'Connor J; Wedel N; Roboz GJ; Miller C; Chopra R; Jurcic JC; Brown R; Ehmann WC; Schulman P; Frankel SR; De Angelo D; Scheinberg D
    J Clin Oncol; 2005 Jun; 23(18):4110-6. PubMed ID: 15961759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.
    Taksin AL; Legrand O; Raffoux E; de Revel T; Thomas X; Contentin N; Bouabdallah R; Pautas C; Turlure P; Reman O; Gardin C; Varet B; de Botton S; Pousset F; Farhat H; Chevret S; Dombret H; Castaigne S
    Leukemia; 2007 Jan; 21(1):66-71. PubMed ID: 17051246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.
    Prebet T; Etienne A; Devillier R; Romeo E; Charbonnier A; D'incan E; Esterni B; Arnoulet C; Blaise D; Vey N
    Cancer; 2011 Mar; 117(5):974-81. PubMed ID: 20957721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
    Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
    Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.
    Hütter-Krönke ML; Benner A; Döhner K; Krauter J; Weber D; Moessner M; Köhne CH; Horst HA; Schmidt-Wolf IG; Rummel M; Götze K; Koller E; Petzer AL; Salwender H; Fiedler W; Kirchen H; Haase D; Kremers S; Theobald M; Matzdorff AC; Ganser A; Döhner H; Schlenk RF
    Haematologica; 2016 Jul; 101(7):839-45. PubMed ID: 27036160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
    Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
    Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
    Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
    Martin MG; Augustin KM; Uy GL; Welch JS; Hladnik L; Goyal S; Tiwari D; Monahan RS; Reichley RM; Cashen AF; Stockerl-Goldstein K; Westervelt P; Abboud CN; Dipersio JF; Vij R
    Am J Hematol; 2009 Nov; 84(11):733-7. PubMed ID: 19806665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
    Cortes J; Tsimberidou AM; Alvarez R; Thomas D; Beran M; Kantarjian H; Estey E; Giles FJ
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):497-500. PubMed ID: 12451477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.